Heteroaromatic selective inhibitors of neuronal nitric oxide synthase
Compounds inhibiting neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, such compounds of a formula.
1. A neuronal nitric oxide synthase inhibitor compound of a formula
wherein X is CH; m and n are 1; Y is N; p and q are 1; Z is selected from NH and O; R 1 is selected from H, alkyl, amino, hydroxyl, and substituted alkyl moieties, said R 1 substituents selected from amino, hydroxy and phenyl substituents; and R 2 is selected from H, alkyl, substituted alkyl, hydroxyalkyl, substituted hydroxyalkyl, aminoalkyl and substituted aminoalkyl moieties, said R 2 substituents selected from alkoxycarbonyl, alkylamido, carbamoyl, pyridinyl, phenylalkyl and phenyl substituents; and a salt thereof.
2. The compound of claim 1 wherein Z is NH, or O, and R 2 is an aminoalkyl moiety.
3. The compound of claim 2 wherein said R 2 moiety is selected from primary, secondary, and tertiary amino groups.
4. The compound of claim 3 wherein R 1 is selected from H and aminoalkyl moieties.
5. The compound of claim 1 wherein Z is NH or O, R 1 is selected from H and aminoalkyl moieties, and R 2 is an aminoalkyl moiety.
6. A neuronal nitric oxide synthase inhibitor compound of a formula
wherein R 1 is selected from H, alkyl, substituted alkyl, aminoalkyl, substituted aminoalkyl, hydroxyalkyl, and substituted hydroxyalkyl moieties, said R 1 substituents selected from amino, hydroxy and phenyl substituents; and R 2 is selected from H, alkyl, substituted alkyl, hydroxyalkyl, substituted hydroxyalkyl, aminoalkyl and substituted aminoalkyl moieties, said R 2 substituents selected from alkoxycarbonyl, alkylamido, carbamoyl, pyridinyl and phenyl substituents; and a salt thereof.
7. The compound of claim 6 wherein R 1 is selected from H and aminoalkyl moieties.
8. The compound of claim 6 wherein R 2 is an aminoalkyl moiety.
9. The compound of claim 8 wherein said R 2 moiety is selected from primary, secondary, and tertiary amino groups.
10. The compound of claim 9 wherein R 1 is selected from H and aminoalkyl moieties.